Biotech3 hours ago
TG Therapeutics Advances Subcutaneous Briumvi With Strong Trial Results and Rising Sales Momentum
TG Therapeutics reported strong Phase 1 results for subcutaneous Briumvi in multiple sclerosis, exceeding expectations in bioavailability, safety, and tolerability. The formulation could significantly expand its...